

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C. 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 03 May 2000 (03.05.00)	
International application No. PCT/GB99/02247	Applicant's or agent's file reference 92573/JND/CH
International filing date (day/month/year) 13 July 1999 (13.07.99)	Priority date (day/month/year) 13 July 1998 (13.07.98)
Applicant SCHMIDT, Günter et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

08 February 2000 (08.02.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer S. Mafla Telephone No.: (41-22) 338.83.38
---	--

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 92573/JND/CH	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/GB 99/ 02247	International filing date (day/month/year) 13/07/1999	(Earliest) Priority Date (day/month/year) 13/07/1998
Applicant BRAX GROUP LIMITED et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form..

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the title,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

SILICON-CONTAINING LINKERS FOR NUCLEIC ACID MASS MARKERS

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☒ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

1
☐ None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/02247

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07H21/00 C12Q1/68 G01N33/58

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 27327 A (DARWIN MOLECULAR CORP ;TABONE JOHN C (US); MULLIGAN JOHN T (US); H) 31 July 1997 (1997-07-31) claims 33-61; figure 13 ---	1,5,6, 18,19, 21-23, 26-28, 30-32
A	SAHA, ASHIS K.; SARDARO, MARK; WAYCHUNAS, CHERYL; DELECKI, DANIEL; KUTNY, RUSTY; AT AL.: "Diisopropylsilyl-Linked Oligonucleotide Analogs: Solid-Phase Synthesis and Physicochemical Properties" JOURNAL OF ORGANIC CHEMISTRY, vol. 58, no. 27, 1993, pages 7827-7831, XP002122242 page 7827 -page 7828 --- -/--	1



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 November 1999

Date of mailing of the international search report

24/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hart-Davis, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/02247

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	WO 99 00402 A (INNOVIR LAB INC) 7 January 1999 (1999-01-07) figures 1,2 -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/02247

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
W0 9727327 A	31-07-1997	AU 1707997 A	20-08-1997
		CA 2243989 A	31-07-1997
		CN 1212019 A	24-03-1999
		CZ 9802183 A	16-12-1998
		EP 0850320 A	01-07-1998
		HU 9900459 A	28-06-1999
		NZ 331042 A	28-10-1999
		PL 328272 A	18-01-1999
W0 9900402 A	07-01-1999	AU 8264298 A	19-01-1999




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07H 21/00, C12Q 1/68, G01N 33/58		A1	(11) International Publication Number: WO 00/02894
			(43) International Publication Date: 20 January 2000 (20.01.00)
(21) International Application Number: PCT/GB99/02247 (22) International Filing Date: 13 July 1999 (13.07.99) (30) Priority Data: 9815164.0 13 July 1998 (13.07.98) GB (71) Applicant (for all designated States except US): BRAX GROUP LIMITED [GB/GB]; 13 Station Road, Cambridge CB1 2JB (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): SCHMIDT, Günter [DE/GB]; Houghton Manor, Houghton, Cambs PE17 2BQ (GB). THOMPSON, Andrew, Hugin [GB/GB]; 25 Knoll Park, Alloway, Ayr KA7 4RH (GB). JOHNSTONE, Robert, Alexander, Walker [GB/GB]; 39 Poulton Road, Bebington L63 9LD (GB). (74) Agents: DANIELS, Jeffrey, Nicholas et al.; Page White & Farrer, 54 Doughty Street, London WC1N 2LS (GB).			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: SILICON-CONTAINING LINKERS FOR NUCLEIC ACID MASS MARKERS

(57) Abstract

Provided is a method for characterising an analyte, which method comprises: (a) providing a compound in which the analyte is attached by a cleavable linker to a reporter group relatable to the analyte, the linker having formula (1): wherein R¹ and R² are substituents as defined in any of claims 1-4 16 and 17; (b) cleaving the reporter group from the analyte; and (c) identifying the reporter group, thereby characterising the analyte.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SILICON-CONTAINING LINKERS FOR NUCLEIC ACID MASS MARKERS

This invention concerns compounds which comprise mass markers for detection by mass spectrometry. The invention relates to methods for characterising nucleic acids or other molecules by labelling with markers that are cleavably detachable from their associated nucleic acid and that are detectable by mass spectrometry. Specifically this invention relates to improved methods of detaching mass labels from their associated nucleic acids or other molecules of interest.

PCT/GB98/00127 describes arrays of cleavable labels that are detectable by mass spectrometry which identify the sequence of a covalently linked nucleic acid probe. These mass labels have a number of advantages over other methods of analysing nucleic acids. At present commercially favoured systems are based on fluorescent labelling of DNA. Fluorescent labelling schemes permit the labelling of a relatively small number of molecules simultaneously, typically 4 labels can be used simultaneously and possibly up to eight. However the costs of the detection apparatus and the difficulties of analysing the resultant signals limit the number of labels that can be used simultaneously in a fluorescence detection scheme. An advantage of using mass labels is the possibility of generating large numbers of labels which have discrete peaks in a mass spectrum allowing similar numbers of distinct molecular species to be labelled simultaneously. Fluorescent dyes are expensive to synthesise whereas mass labels can comprise relatively simple polymers permitting combinatorial synthesis of large numbers of labels at low cost.


A feature of the mass labelling techniques disclosed in PCT/GB98/00127 is the need for linker groups that covalently link a mass marker to its corresponding nucleic acid. These linkers must permit the mass marker to be separated from its nucleic acid prior to detection within a mass spectrometer. It is desirable that the cleavage of the label from its nucleic acid be performed in-line with a mass spectrometer, possibly after some in-line pre-fractionation step such as capillary electrophoresis. It is also desirable that this in-line cleavage step does not require a complex interface with the mass spectrometer to enable this step to occur. Ideally

linkers should cleave at some predetermined point within existing instruments without any modification to the instrument beyond changes of normal operating parameters.

Linkers should cleave without damaging associated nucleic acids hence reducing noise in the mass spectrum from nucleic acid fragmentation. Linkers should all cleave under the same conditions to ensure all labels can be analysed simultaneously and quantitatively.

It is an object of this invention to provide linkers that have the desired features disclosed above which are compatible with existing mass spectrometers particularly electrospray ionisation and tandem mass spectrometry.

Accordingly, the present invention provides a compound having the following formula (I):




wherein M comprises a mass marker, N comprises a nucleic acid and R¹ and R² are substituents selected such that when the compound reacts with an electron donating moiety, either N or M cleaves from the Si atom in preference to R¹ and R².

Compounds with the formula (I) shown above meet the specification discussed above. The molecule is stable during synthesis and can be cleaved under mild conditions in an electrospray ion source or in the collision chamber of a tandem mass spectrometer in the presence of an appropriately reactive gaseous electron donating moiety, such as ammonia. The reactive gas participates in a novel gas phase reaction with the linker resulting in the cleavage of the linker.

The present invention also provides a method for characterising an analyte, which method comprises:


- (a) providing a compound in which the analyte is attached by a cleavable linker to a reporter group relatable to the analyte, the linker having the following formula:



wherein R¹ and R² are substituents as defined below;

- (b) cleaving the reporter group from the analyte; and
(c) identifying the reporter group, thereby characterising the analyte.

The invention additionally provides use of a linker group in the characterisation of an analyte, to attach a reporter group to the analyte, wherein the linker group is cleavable and has the following formula:



wherein R¹ and R² are substituents as defined below.

The invention will now be described in further detail by way of example only, with reference to the accompanying drawings, in which:

Figure 1 depicts the mechanism of cleavage of a linker used in the present invention, by means of a primary amine. Cleavage takes place via a five-co-ordinate intermediate to produce two possible products. The mass spectrum of the charged products is measured;

Figure 2 shows the negative ion mass spectrum of FT23 at 0.35 pmol/ μ l. This spectrum shows a very clean molecular ion less 1 proton at m/z 729.4;

Figure 3 shows the positive ion mass spectrum of FT23 at 0.35 pmol/ μ l. This spectrum shows a strong protonated molecular ion peak at m/z 731.5 and a second stronger peak at m/z 753.3 corresponding to a sodium adduct of FT23;

Figure 4 shows the negative ion mass spectrum of FT23 at 0.35 pmol/ μ l in the presence of a PCR product. The molecular ion is not detectable over the background peaks;

Figure 5 shows the positive ion mass spectrum of FT23 at 0.35 pmol/ μ l in the presence of a PCR product. This spectrum does not show any of the protonated molecular ion peak at m/z 731.4 or the sodium adduct peak at m/z 753.3. Two additional peaks of significance appear in this spectrum. One peak at m/z 739.2 and a second peak at m/z 755.2. These peaks are believed to be end-products of a novel gas phase cleavage reaction discussed below. The two peaks corresponding to gas phase cleavage products are the only major ion peaks in this spectrum; and

Figure 6 shows a reaction mechanism for ammonia reacting with a TBDMS protective group used in the present invention.

In the methods of the present invention, the analyte is not particularly limited and can be any analyte or molecule of interest, such as a nucleic acid or other molecule. Typically the analyte comprises a biological molecule. In preferred embodiments of the present invention, the biological molecule is selected from a protein, a polypeptide, an amino acid, a nucleic acid (e.g. an RNA, a DNA, a plasmid, a nucleotide or an oligonucleotide), a nucleic acid base, a pharmaceutical agent or drug, a carbohydrate, a lipid, a natural product and a synthetic compound from an encoded chemical library. When the analyte comprises a nucleotide, oligonucleotide or nucleic acid, the nucleotide, oligonucleotide or nucleic acid may be natural,

or may be modified by modifying a base, sugar and/or backbone of the nucleotide, oligonucleotide or nucleic acid. In the compounds of the present invention, the analyte is a nucleic acid, and may be any type of nucleic acid. Preferably, the nucleic acid is of a type as defined above.

The substituents R^1 and R^2 are not especially limited. It is preferred that R^1 and R^2 are selected such that their bond energies to Si are greater than the bond energy of N and/or M to Si to ensure that when the compound is reacted with an electron donating moiety either N or M cleaves from the Si atom in preference to R^1 and R^2 , and/or R^1 and R^2 are selected such that their steric bulk is sufficient to ensure that when the compound is reacted with an electron donating moiety either N or M cleaves from the Si atom in preference to R^1 and R^2 . Typically, R^1 and R^2 are each independently a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, or a substituted or unsubstituted aryl group. It is particularly preferred that R^1 and R^2 are each independently fluorine, chlorine, bromine, iodine, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl or phenyl groups.

Thus, various substituents may be introduced at the positions R^1 and R^2 including fluorine, chlorine and other halogens, methyl, ethyl and other alkyl groups. Phenyl groups may also be appropriate. Preferably substituents at R^1 and R^2 should be stable during synthesis of the marker, during incorporation of the mass label into an oligonucleotide in an automated synthesiser and under mass spectrometry. A wide variety of groups have these properties and may be incorporated into the linker at these positions. It may also be desirable in some embodiments to choose substituents which change the solubility of the linker and alter the rigidity of the linker.

Preferably a covalent linkage is formed in attaching the analyte and/or the reporter group to the cleavable linker. The covalent linkage is not particularly limited provided that the analyte and/or reporter group can readily be attached to the cleavable linker using reactive functionalities attached to the linker and the analyte.

Table 1 below lists some reactive functionalities that may be reacted together to generate a covalent linkage between two entities. Any of the functionalities listed below could be used to form the compounds used in the present invention to permit the linker to be attached to an analyte (such as a nucleic acid or protein) for detection (e.g. by mass spectrometry). If desired, a reactive functionality can be used to introduce a further linking group with a further reactive functionality.

Table 1

Functionality 1	Functionality 2	Resultant Covalent Linkage
-NH ₂	-COOH	-CO-NH-
-NH ₂	-NCO	-NH-CO-NH-
-NH ₂	-NCS	-NH-CS-NH-
-NH ₂	-CHO	-CH ₂ -NH-
-NH ₂	-SO ₂ Cl	-SO ₂ -NH-
-NH ₂	-CH=CH-	-NH-CH ₂ -CH ₂ -
-OH	-OP(NCH(CH ₃) ₂) ₂	-OP(=O)(O)O-

It should be noted that some of the reactive functionalities above or their resultant covalent linkages might have to be protected prior to introduction into an oligonucleotide synthesiser. Preferably unprotected ether, ester, thioether and thioesters, amine and amide bonds are to be avoided as these are not stable in an oligonucleotide synthesiser. A wide variety of protective groups are known in the art to protect linkages from unwanted side reactions.

A short alkyl linkage is appropriate to link the mass marker to the linker, although a wide variety of linkages are available which can be used to link a mass marker to a linker.

The reporter group used in the present invention is not especially limited and may be any group, provided that it is readily detectable and can be related to an analyte to identify the analyte. Typically, the reporter group is a mass marker, that is detectable by mass spectrometry. Other appropriate reporters include fluorophores, radiolabels, chemiluminescent

labels, and electron capture labels. In the compounds of the present invention, the reporter group comprises a mass marker.

In preferred embodiments of the present invention, mass markers disclosed in PCT/GB98/00127, PCT/GB98/03842, GB 9815166.5 and GB 9826159.7 can be employed. The content of these applications is incorporated by reference. PCT/GB98/00127 and PCT/GB98/03842 disclose poly-ether mass markers which are thermally stable, chemically inert and fragmentation resistant compounds, and which can be substituted with a variety of groups to alter properties such as solubility and charge. These mass markers are also preferred for use in the present invention and the content of this application is incorporated by reference. GB 9826159.7 discloses markers which comprise two components, which may be poly-ethers, which are analysed by selected reaction monitoring. These are particularly preferred mass markers for use in the present invention. GB 9815166.5 discloses mass markers that bind metal ions, which are also preferred markers for use with this invention. The content of this application is incorporated by reference. Reporter groups that can be detected by more than one detection means may also be desirable as with, for example, a fluorescent marker that incorporates a radioisotope in its linker and that is detectable by mass spectrometry and reporters of this kind are referred to as 'multi-mode reporter' groups. Preferred multi-mode reporter groups are detectable by mass spectrometry.

When the mass marker comprises an oligoether or a polyether, the oligoether or polyether may be a substituted or unsubstituted oligo- or poly-arylether. The oligoether or polyether preferably comprises one or more fluorine atom or methyl group substituents, or one or more ^2H or ^{13}C isotopic substituents.

It is further preferred that the mass marker comprises a metal ion-binding moiety. Typically, the metal ion-binding moiety comprises a porphyrin, a crown ether, hexahistidine, or a multidentate ligand. Preferably, the metal ion-binding moiety is a bidentate ligand or is EDTA. The metal ion-binding moiety may be bound to a monovalent, divalent or trivalent metal ion. The metal ion is not especially limited. Preferred metal ions include a transition

metal ion, or a metal ion of group IA, IIA or IIIA of the periodic table. Particularly preferred metal ions are Ni^{2+} , Li^{+} , Na^{+} , K^{+} , Mg^{2+} , Ca^{2+} , Sr^{2+} , Ba^{2+} , or Al^{3+} . The presence of a metal ion on the mass marker increases the sensitivity of detection.

It should be noted that this invention is not limited to the mass markers disclosed in the above applications. Any molecule with the correct features can be used as a mass marker. Desirable features include:

- Easily detachable from DNA
- Fragmentation resistant in mass spectrometer
- Single ion peaks
- Very sensitive detection
- Easily distinguishable from background contamination
- Distinguish from DNA
- Be certain that a mass peak is from a mass label
- Compatible with oligonucleotide synthesiser
- Easy to synthesise in a combinatorial manner to minimise number of chemical steps and the number of reagents necessary to generate large number of labels
- Compatible with existing mass spectrometry instrumentation without requiring physical modification.

Mass labels and their linkers can be attached to a nucleic acid molecule at a number of locations in the nucleic acid. For conventional solid phase synthesisers the 5' hydroxyl of the sugar is the most readily accessible. Other favoured positions for modifications are on the base at the 5' position in the pyrimidines and the 7' and 8' positions in the purines. These would all be appropriate positions to attach a cleavable mass with the linker of this invention.

The 2' position on the sugar is accessible for mass modifications but is more appropriate for small mass modifications that are not to be removed.

The phosphate linkage in natural nucleic acids can be modified to a considerable degree as well, including derivitisation with mass labels.


The cleavable linker used in this invention may be cleaved in the ion source of a mass spectrometer by ammonia. However, this invention is not limited to the use of ammonia. Most amines are capable of separating the mass marker from its cognate oligonucleotide and other nucleophiles may also be used.

The invention will now be described in further detail by way of example only, with reference to the following specific embodiments.

Examples

Synthesis of a mass labelled nucleotide FT23

A thymidine residue with a poly-aryl ether mass label was synthesised as a model compound, shown below:



TBDMS=Tertiary butyl dimethylsilyl

A solution of 5'-O-(tert-butyl dimethylsilyl)-3'-succinyl-thymidine (288 mg, 0.5 mmol) in dichloromethane (3 ml) was treated with three drops of pyridine and then dropwise with a

2 M solution of oxalyl chloride (0.3 ml, 0.6 mmol) in dichloromethane. The reaction mixture was stirred for 90 min at room temp. The solution of the formed acid chloride was added dropwise to an ice-cold solution of (4'-phenoxy)-4-phenoxybenzyl alcohol (146 mg, 0.5 mmol) and pyridine (0.3 ml) in dichloromethane (3 ml). Stirring was continued for 4 h at room temperature. The reaction mixture was diluted with ethyl acetate and washed with a 5 % aqueous solution of NaHCO_3 and twice with water. The organic phase was dried with sodium sulphate and the solvent was removed under reduced pressure. The residue was purified by flash chromatography with ethyl acetate/n-hexane (1:1) to yield 73 mg (20 %) of FT 23.

^1H NMR (CDCl_3): 0.13 (6 H, s); 0.92 (9 H, s); 1.92 (3 H, s); 2.11 (1 H, m); 2.39 (1 H, m); 2.68 (4 H, s); 3.90 (2 H, d); 4.06 (1 H, d); 5.11 (2 H, s); 5.27 (1 H, d); 6.34 (1 H, m); 6.95-7.37 (13 H, m); 7.35 (1 H, d); 8.27 (1 H, br s).

The product of the synthesis was analysed by ESI MS to determine whether the predicted molecular ions were present. The protonated molecular ion was detected at m/z 731 and the molecular less 1 proton was detected at m/z 729. (Mass spectra shown in Figures 4 and 5 respectively)

Mass Spectrometry Analysis of FT23

All data was acquired on a Platform-LC quadrupole instrument (Micromass Ltd, UK) with an electrospray ionisation source.

Figure 2 shows the negative ion mass spectrum of FT23 at 0.35 pmol/ μl . This spectrum shows a very clean molecular ion less 1 proton at m/z 729.4.

Figure 3 shows the positive ion mass spectrum of FT23 at 0.35 pmol/ μl . This spectrum shows a strong protonated molecular ion peak at m/z 731.5 and a second stronger peak at m/z 753.3 corresponding to a sodium adduct of FT23. Without being bound by theory, it is believed that the poly-ether mass label with the succinate linker is behaving in a similar manner to a crown ether and is binding strongly to sodium to generate these sodium adducts.

Figure 4 shows the negative ion mass spectrum of FT23 at 0.35 pmol/ μ l in the presence of a PCR product. The molecular ion is not detectable over the background peaks.

Figure 5 shows the positive ion mass spectrum of FT23 at 0.35 pmol/ μ l in the presence of a PCR product. This spectrum does not show any of the protonated molecular ion peak at m/z 731.4 or the sodium adduct peak at m/z 753.3. Two additional peaks of significance appear in this spectrum. One peak at m/z 739.2 and a second peak at m/z 755.2. These peaks are believed to be end-products of a novel gas phase cleavage reaction discussed below. The two peaks corresponding to gas phase cleavage products are the only major ion peaks in this spectrum.

FT23 is a thymidine derivative which has been protected on the 5' hydroxyl using a tert-butyl dimethylsilyl (TBDMS) protective group. Without being bound by theory, it is believed that in this invention a small quantity of ammonia present in the sample, introduced with the PCR product reacts with the TBDMS protective group according to the mechanism shown in Figure 6. Water appears to react with the TBDMS group to some extent as well. The chemical reactions which take place do not have any charged intermediates. The reaction is visible in the mass spectrometer because of the sodium ion binding behaviour of the mass label used in these studies. The lack of any protonated ions suggest that sodium binding is very strong and that an excess of sodium ions is present which binds to all of the FT23 present. This gives rise to sodium adducts which have a single positive charge. Nucleophilic attack by ammonia generates a trigonal pyramidal intermediate which is energetically unstable. This intermediate rearranges itself with the loss of formyl amine to generate an ion with m/z 739. Similarly nucleophilic attack by water generates a trigonal pyramidal intermediate which is energetically unstable. This intermediate rearranges itself with the loss of methane to generate an ion with m/z 755.


These cleavage product peaks are seen as the majority ions when 0.35 pmol/ μ l of FT23 is analysed in the positive ion mode in the presence of a PCR product (Figure 5) but are not

observed when the pure compound is analysed (Figure 3). At higher concentrations of FT23 the singly protonated molecular ion peaks are still detectable in the presence of nucleic acid (not shown). In the negative ion mode the pure compound is readily detected at 0.35 pmol/ μ l but is not detectable at the same concentration in the presence of a PCR product. Ammonia was present in the buffers of the PCR product. The spectra are interpretable if the low levels of ammonia are cleaving the silyl protective group. The levels of ammonia are limiting - at higher concentrations of FT23 the reaction does not go to completion (not shown) but at the lower concentration of FT23 there is sufficient ammonia to completely cleave the molecular ion.

Figure 1 shows how this chemistry can be adapted for use as a gas phase cleavable linker as discussed above.

CLAIMS:

1. A compound having the following formula (I):



wherein M comprises a mass marker, N comprises a nucleic acid and R¹ and R² are substituents selected such that when the compound reacts with an electron donating moiety, either N or M cleaves from the Si atom in preference to R¹ and R².

2. A compound according to claim 1, wherein R¹ and R² are selected such that their bond energies to Si are greater than the bond energy of N and/or M to Si to ensure that when the compound is reacted with an electron donating moiety either N or M cleaves from the Si atom in preference to R¹ and R², and/or R¹ and R² are selected such that their steric bulk is sufficient to ensure that when the compound is reacted with an electron donating moiety either N or M cleaves from the Si atom in preference to R¹ and R².


3. A compound according to claim 1 or claim 2, wherein R¹ and R² are each independently a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, or a substituted or unsubstituted aryl group.

4. A compound according to claim 3, wherein R¹ and R² are each independently fluorine, chlorine, bromine, iodine, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl or phenyl groups.

5. A compound according to any preceding claim, wherein N comprises a nucleotide or an oligonucleotide.
6. A compound according to claim 5, wherein the nucleotide or oligonucleotide is natural, or is modified by modifying a base, sugar and/or backbone of the nucleotide or oligonucleotide.
7. A compound according to any preceding claim, wherein the mass marker comprises a polyether.
8. A compound according to claim 7, wherein the polyether is a substituted or unsubstituted poly(arylether).
9. A compound according to claim 7 or claim 8, wherein the polyether comprises one or more fluorine atom substituents.
10. A compound according to any preceding claim, wherein the mass marker comprises a metal ion-binding moiety.
11. A compound according to claim 10, wherein the metal ion-binding moiety is a porphyrin, a crown ether, hexahistidine, or a multidentate ligand.
12. A compound according to claim 11, wherein the metal ion-binding moiety is a bidentate ligand or is EDTA.
13. A compound according to any of claims 10-12, wherein the metal ion-binding moiety is bound to a monovalent, divalent or trivalent metal ion.
14. A compound according to claim 13, wherein the metal ion is a transition metal ion, or a metal ion of group IA, IIA or IIIA of the periodic table.

15. A compound according to claim 14, wherein the metal ion is Ni^{2+} , Li^{+} , Na^{+} , K^{+} , Mg^{2+} , Ca^{2+} , Sr^{2+} , Ba^{2+} , or Al^{3+} .
16. A compound according to any preceding claim, wherein the electron donating moiety is a Lewis base.
17. A compound according to claim 16, wherein the Lewis base is ammonia; a primary, secondary or tertiary amine; a compound containing a hydroxy group; an ether; or water.
18. A method for characterising an analyte, which method comprises:
- providing a compound in which the analyte is attached by a cleavable linker to a reporter group relatable to the analyte, the linker having the following formula:
$$\begin{array}{c} \text{R}^2 \\ | \\ \text{---Si---} \\ | \\ \text{R}^1 \end{array}$$
 - wherein R^1 and R^2 are substituents as defined in any of claims 1-4 16 and 17;
 - cleaving the reporter group from the analyte; and
 - identifying the reporter group, thereby characterising the analyte.
19. A method according to claim 18, wherein the reporter group is a mass marker identifiable by mass spectrometry.
20. A method according to claim 19, wherein the mass marker is as defined in any of claims 7-15.
21. A method according to any of claims 18-20, wherein the analyte is a nucleic acid.

22. A method according to claim 21, wherein the nucleic acid is as defined in claim 5 or claim 6.
23. A method according to any of claims 18-22, which method further comprises forming a compound as defined in any of claims 1-17, prior to identifying the reporter group.
24. A method according to any of claims 18-23, which method further comprises contacting the linker with an electron donating moiety to cleave off the reporter group.
25. A method according to claim 24, wherein the electron donating moiety is as defined in claim 16 or claim 17.
26. A method according to any of claims 18-25, wherein the reporter group is a mass marker and the method further comprises cleaving off the mass marker in a mass spectrometer.
27. Use of a linker group in the characterisation of an analyte, to attach a reporter group to the analyte, wherein the linker group is cleavable and has the following formula:




wherein R¹ and R² are substituents as defined in any of claims 1-4, 16 and 17.


28. Use according to claim 27, wherein the analyte is a mass marker identifiable by mass spectrometry.


29. Use according to claim 28, wherein the mass marker is as defined in any of claims 7-15.
30. Use according to any of claims 27-29, wherein the analyte is a nucleic acid.
31. Use according to claim 30, wherein the nucleic acid is as defined in claim 5 or claim 6.
32. Use according to any of claims 27-31, wherein the mass marker forms part of a compound as defined in any of claims 1-17.

Fig. 1.



2/6







4/6

Fig. 4.

FT23 + PCR Product (-ve Ion) 0.35 pm/ μ l
(PCR Product mol wt \approx 200,000)




5/6



6/6

Fig.6.



INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/02247

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07H21/00 C12Q1/68 G01N33/58

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 27327 A (DARWIN MOLECULAR CORP ;TABONE JOHN C (US); MULLIGAN JOHN T (US); H) 31 July 1997 (1997-07-31) claims 33-61; figure 13 ---	1, 5, 6, 18, 19, 21-23, 26-28, 30-32
A	SAHA, ASHIS K.; SARDARO, MARK; WAYCHUNAS, CHERYL; DELECKI, DANIEL; KUTNY, RUSTY; AT AL.: "Diisopropylsilyl-Linked Oligonucleotide Analogs: Solid-Phase Synthesis and Physicochemical Properties" JOURNAL OF ORGANIC CHEMISTRY, vol. 58, no. 27, 1993, pages 7827-7831, XP002122242 page 7827 -page 7828 --- -/--	1

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "3" document member of the same patent family

Date of the actual completion of the international search

10 November 1999

Date of mailing of the international search report

24/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Hart-Davis, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/02247

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	WO 99 00402 A (INNOVIR LAB INC) 7 January 1999 (1999-01-07) figures 1,2 ----- -----	1 -

INTERNATIONAL SEARCH REPORT

Information on patent family members


International Application No

PL/GB 99/02247

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9727327 A	31-07-1997	AU 1707997 A	20-08-1997
		CA 2243989 A	31-07-1997
		CN 1212019 A	24-03-1999
		CZ 9802183 A	16-12-1998
		EP 0850320 A	01-07-1998
		HU 9900459 A	28-06-1999
		NZ 331042 A	28-10-1999
		PL 328272 A	18-01-1999
WO 9900402 A	07-01-1999	AU 8264298 A	19-01-1999

CLAIMS:

1. A compound having the following formula (I):



wherein M comprises a mass marker, N comprises a nucleic acid and R¹ and R² are substituents selected such that when the compound reacts with an electron donating moiety, either N or M cleaves from the Si atom in preference to R¹ and R².

2. A compound according to claim 1, wherein R¹ and R² are selected such that their bond energies to Si are greater than the bond energy of N and/or M to Si to ensure that when the compound is reacted with an electron donating moiety either N or M cleaves from the Si atom in preference to R¹ and R², and/or R¹ and R² are selected such that their steric bulk is sufficient to ensure that when the compound is reacted with an electron donating moiety either N or M cleaves from the Si atom in preference to R¹ and R².

3. A compound according to claim 1 or claim 2, wherein R¹ and R² are each independently a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, or a substituted or unsubstituted aryl group.

4. A compound according to claim 3, wherein R¹ and R² are each independently fluorine, chlorine, bromine, iodine, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl or phenyl groups.

5. A compound according to any preceding claim, wherein N comprises a nucleotide or an oligonucleotide.
6. A compound according to claim 5, wherein the nucleotide or oligonucleotide is natural, or is modified by modifying a base, sugar and/or backbone of the nucleotide or oligonucleotide.
7. A compound according to any preceding claim, wherein the mass marker comprises a polyether.
8. A compound according to claim 7, wherein the polyether is a substituted or unsubstituted poly(arylether).
9. A compound according to claim 7 or claim 8, wherein the polyether comprises one or more fluorine atom substituents.
10. A compound according to any preceding claim, wherein the mass marker comprises a metal ion-binding moiety.
11. A compound according to claim 10, wherein the metal ion-binding moiety is a porphyrin, a crown ether, hexahistidine, or a multidentate ligand.
12. A compound according to claim 11, wherein the metal ion-binding moiety is a bidentate ligand or is EDTA.
13. A compound according to any of claims 10-12, wherein the metal ion-binding moiety is bound to a monovalent, divalent or trivalent metal ion.
14. A compound according to claim 13, wherein the metal ion is a transition metal ion, or a metal ion of group IA, IIA or IIIA of the periodic table.


15. A compound according to claim 14, wherein the metal ion is Ni^{2+} , Li^{+} , Na^{+} , K^{+} , Mg^{2+} , Ca^{2+} , Sr^{2+} , Ba^{2+} , or Al^{3+} .

16. A compound according to any preceding claim, wherein the electron donating moiety is a Lewis base.

17. A compound according to claim 16, wherein the Lewis base is ammonia; a primary, secondary or tertiary amine; a compound containing a hydroxy group; an ether; or water.

18. A method for characterising an analyte, which method comprises:

- (a) providing a compound in which the analyte is attached by a cleavable linker to a reporter group relatable to the analyte, the linker having the following formula:



wherein R^1 and R^2 are substituents as defined in any of claims 1-4 16 and 17;


- (b) cleaving the reporter group from the analyte; and
(c) identifying the reporter group, thereby characterising the analyte.

19. A method according to claim 18, wherein the reporter group is a mass marker identifiable by mass spectrometry.

20. A method according to claim 19, wherein the mass marker is as defined in any of claims 7-15.

21. A method according to any of claims 18-20, wherein the analyte is a nucleic acid.

22. A method according to claim 21, wherein the nucleic acid is as defined in claim 5 or claim 6.
23. A method according to any of claims 18-22, which method further comprises forming a compound as defined in any of claims 1-17, prior to identifying the reporter group.
24. A method according to any of claims 18-23, which method further comprises contacting the linker with an electron donating moiety to cleave off the reporter group.
25. A method according to claim 24, wherein the electron donating moiety is as defined in claim 16 or claim 17.
26. A method according to any of claims 18-25, wherein the reporter group is a mass marker and the method further comprises cleaving off the mass marker in a mass spectrometer.
27. Use of a linker group in the characterisation of an analyte, to attach a reporter group to the analyte, wherein the linker group is cleavable and has the following formula:



wherein R¹ and R² are substituents as defined in any of claims 1-4, 16 and 17.

28. Use according to claim 27, wherein the analyte is a mass marker identifiable by mass spectrometry.

29. Use according to claim 28, wherein the mass marker is as defined in any of claims 7-15.
30. Use according to any of claims 27-29, wherein the analyte is a nucleic acid.
31. Use according to claim 30, wherein the nucleic acid is as defined in claim 5 or claim 6.
32. Use according to any of claims 27-31, wherein the mass marker forms part of a compound as defined in any of claims 1-17.